Lumenis, the inventor of IPL, presents the first and only IPL FDA-approved for the management of dry eye disease due to MGD.

Introducing OptiLIGHT – a bright solution for dry eyes. OptiLIGHT elevates dry eye management with Lumenis’ patented Optimal Pulse Technology (OPT™) and user-centered design. Get the safe, precise, elegant procedure you want and the comfortable, effective therapy your patients need to manage dry eye disease with OptiLIGHT, a dry eye medical device.

What is OptiLIGHT?

OptiLIGHT is a light-based treatment that uses precise, intense broad spectrum light to address signs of dry eye disease due to meibomian gland dysfunction (MGD). MGD is the most common cause of dry eye disease, accounting for about 86% of cases8. The treatment addresses inflammation, which is one of the key underlying factors in MGD. OptiLIGHT was specifically developed to reach the delicate contours of the treated area safely, effectively, and gently using the OPT™ technology. It is intended for use in patients who are at least 22 years old, together with other available treatments, such as Meibomian gland expression, artificial tear lubricants, and warm compresses.

How OptiLIGHT Help with Dry Eye

• Reduce Inflammatory Mediators: Decrease the level of pro-inflammatory mediators to inhibit inflammation.
• Improve Tear Breakup Time: Significantly boost tear break up time and decrease osmolarity.
• Alleviate Abnormal Blood Vessels: Cauterize overactive capillaries that perpetuate inflammation.
• Restore Meibomian Glands: Improve meibomian gland morphology and functionality.
• Decrease Demodex: Decrease the population of Demodex mites, which stimulate infection and boost the bacterial load on eyelids

Consult with an Eye Doctor

It's important to consult with an eye doctor to determine if OptiLIGHT is the right choice for your specific needs and to ensure proper fitting and care.